Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935623 | 0.77 | LMNA (0.42) | LMNA | |
| SCHEMBL4939489 | 0.75 | LMNA (0.33) | LMNAMAPK8MAPK9 | |
| SCHEMBL4821031 | 0.73 | IDH1 (0.33) | LMNACTSSCTSK | |
| SCHEMBL4821037 | 0.73 | IDH1 (0.33) | LMNACTSSCTSK | |
| SCHEMBL4932061 | 0.72 | MAPT (0.41) | LMNAJAK2 | |
| SCHEMBL5164507 | 0.71 | NPC1 (0.34) | — | |
| SCHEMBL5167350 | 0.70 | — | — | |
| SCHEMBL4937597 | 0.70 | LMNA (0.31) | LMNA | |
| SCHEMBL4132149 | 0.66 | CTSL (0.34) | — | |
| SCHEMBL27876511 | 0.66 | LMNA (0.39) | CNR1CNR2LMNACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132522-A1 | 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | US | disclosed |
| EP-1768972-A1 | 2-SUBSTITUTED PYRIMIDINES, METHOD FOR THEIR PRODUCTION AND THEIR USE FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006005571-A1 | 2-SUBSTITUTED PYRIMIDINES, METHOD FOR THEIR PRODUCTION AND THEIR USE FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132522-A1 | 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi | TYMS, TYMP, PNPO | CNR1 1902/4885CNR2 1373/4885LMNA 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.